MAPT and Alzheimer disease: Most importantly hippocampal AAV-NF-α1/CPE treatment promoted mitochondrial Bcl2-, and serpina3g- mediated cell survival mechanisms, down-regulated APP transcription and reduced insoluble Aβ42 production and tau hyperphosphorylation to alleviate cognitive dysfunction in 3xTg-AD mice.